The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ELEVATION ONCOLOGY INC COM 28623U101 14,268 2,370,142 SH   SOLE   2,370,142 0 0
ICOSAVAX INC COM 45114M109 80,314 3,510,228 SH   SOLE   3,510,228 0 0
JASPER THERAPEUTICS INC COM 471871103 45,946 5,852,982 SH   SOLE   5,852,982 0 0
KEZAR LIFE SCIENCES INC COM 49372L100 13,856 828,711 SH   SOLE   828,711 0 0
TALARIS THERAPEUTICS INC COM 87410C104 44,840 2,932,606 SH   SOLE   2,932,606 0 0
VENTYX BIOSCIENCES INC COM 92332V107 18,079 910,306 SH   SOLE   910,306 0 0